eligibility_summary
Adults 18–70 with histologically confirmed advanced/metastatic solid tumors that are refractory or intolerant to standard therapy, CD70-positive, at least one measurable lesion (RECIST v1.1), ECOG 0–1, life expectancy >12 weeks, adequate organ function, able to understand and sign informed consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06730659 tests CHT101, an allogeneic “off‑the‑shelf” CD70‑directed CAR‑T cell therapy (biologic, UCAR‑T) given IV to adults with relapsed/refractory CD70‑positive solid tumors. Mechanism: gene‑engineered T cells express a CAR that binds CD70 on tumor cells, activating CAR signaling (CD3ζ/costimulatory domains) to drive T‑cell activation, cytokine release, and targeted cytolysis independent of native TCR. Targets: CD70 on tumor cells and the CD70–CD27 axis, engages T‑cell effector pathways to eliminate CD70‑expressing cancer cells and modulate the tumor microenvironment. Phase 1, single‑arm dose escalation/expansion assessing safety, PK, and preliminary efficacy.